Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review
Authors:
- 4 June 2016
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 57 (1) , 23-38
Abstract
Celiac disease is a common inflammatory disorder with a prevalence of 1–2 % in which a distinct dietary wheat, rye, and barley component, gluten, induces small-bowel mucosal villous atrophy, crypt hyperplasia, and inflammation. The small-bowel mucosal damage can be reversed by a strict lifelong gluten-free diet, which is currently the only effective treatment for the condition. A key player in the pathogenetic process leading to the enteropathy is played by a protein called transglutaminase 2 (TG2), which is able to enzymatically modify gluten-derived gliadin peptides. The TG2-catalyzed deamidation of the gliadin peptides results in their increased binding affinity to the disease-predisposing human leukocyte antigen (HLA) DQ2 and DQ8 molecules, thus enabling a strong immune response to be launched. Blocking the enzymatic activity of TG2 has thus been suggested as a suitable novel pharmacological approach to treat celiac disease. By virtue of its transamidation capacity, TG2 is also able to cross-link gliadin peptides to itself, this resulting in the generation of TG2-gliadin peptide complexes whose presence might provide an explanation for the generation of the TG2 autoantibodies characteristic of celiac disease. Due to their excellent specificity for the disorder, the TG2-targeted autoantibodies are widely used in the diagnostics as a first-line test to select patients for gastrointestinal endoscopy. More recently, it has come to be appreciated that these autoantibodies and also the TG2-specific B cells might play an active role in the disease pathogenesis. In this review, we assess the role of TG2, TG2-specific B cells, and autoantibodies in celiac disease.Keywords
Funding Information
- Terveyden Tutkimuksen Toimikunta
- Sigrid Juséliuksen Säätiö
- Päivikki ja Sakari Sohlbergin Säätiö
- Suomen Lääketieteen Säätiö
- Competitive State Research Financing of the Expert Responsibility Areas of Tampere University Hospital (9T058)
This publication has 174 references indexed in Scilit:
- Down Syndrome Is Associated with Elevated Risk of Celiac Disease: A Nationwide Case-Control StudyThe Journal of Pediatrics, 2013
- Degree of Damage to the Small Bowel and Serum Antibody Titers Correlate With Clinical Presentation of Patients With Celiac DiseaseClinical Gastroenterology and Hepatology, 2013
- A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effectsProceedings of the National Academy of Sciences of the United States of America, 2011
- Activation of Extracellular Transglutaminase 2 by ThioredoxinJournal of Biological Chemistry, 2011
- Redox Regulation of Transglutaminase 2 ActivityJournal of Biological Chemistry, 2010
- Detection of Celiac Disease and Lymphocytic Enteropathy by Parallel Serology and Histopathology in a Population-Based StudyGastroenterology, 2010
- Diagnosing Mild Enteropathy Celiac Disease: A Randomized, Controlled Clinical StudyGastroenterology, 2009
- Comparative Usefulness of Deamidated Gliadin Antibodies in the Diagnosis of Celiac DiseaseClinical Gastroenterology and Hepatology, 2008
- Reprogramming of CTLs into natural killer–like cells in celiac diseaseJournal of Experimental Medicine, 2006
- Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: A prospective and randomized clinical studyScandinavian Journal of Gastroenterology, 2005